CANCER GENETICS, INC (42) | Transition Agreements (1)

Recent Contracts

Transition Services Agreement, dated July 15, 2019, by and between Interpace BioPharma, Inc. and Cancer Genetics, Inc (Filed With SEC on July 19, 2019)